Merck & Co Inc

NYSE:MRK   3:59:59 PM EDT
-0.48 (-0.60%)
4:22:32 PM EDT: $79.50 +0.11 (+0.14%)
Earnings Announcements

Merck & Co Inc Says Lynparza Improved Median Progression-Free Survival To Over 4.5 Years Vs 13.8 Months With Placebo

Published: 09/18/2020 11:26 GMT
Merck & Co Inc (MRK) - Lynparza® (olaparib) Improved Median Progression-free Survival to Over Four and a Half Years Compared to 13.8 Months With Placebo for Patients With Brca-mutated Advanced Ovarian Cancer.
Merck & Co Inc - Five-year Follow-up Data From Phase 3 Solo-1 Trial Showed Lynparza Reduced Risk of Disease Progression Or Death by 67%.
Merck & Co Inc - at Five Years, 48.3% of Patients Treated With Lynparza Remained Free From Disease Progression Versus.
20.5% on Placebo.
Merck & Co Inc - Safety Profile of Lynparza Was Consistent With Previous Observations in Solo-1.
Merck & Co Inc - Twelve Percent of Patients on Lynparza Discontinued Treatment Due to an Adverse Reaction.
Revenue is expected to be $12.63 Billion
Adjusted EPS is expected to be $1.60

Next Quarter Revenue Guidance is expected to be $13.46 Billion
Next Quarter EPS Guidance is expected to be $1.79

More details on our Analysts Page.